Morgan Stanley Incyte Corp Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Incyte Corp stock. As of the latest transaction made, Morgan Stanley holds 2,594,756 shares of INCY stock, worth $212 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,594,756

Previous 3,029,856 14.36%

Holding current value

$212 Million

Previous $183 Million 3.68%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$55.17 - $71.22 $24 Million - $31 Million	-435,100 Reduced 14.36%	2,594,756 $177 Million
Q1 2025 May 15, 2025	BUY	$60.0 - $75.26 $11.6 Million - $14.5 Million	192,769 Added 6.79%	3,029,856 $183 Million
Q4 2024 Feb 14, 2025	BUY	$65.08 - $83.38 $45 Million - $57.6 Million	690,779 Added 32.18%	2,837,087 $196 Million
Q3 2024 May 14, 2025	SELL	$57.33 - $68.61 $6.2 Million - $7.42 Million	-108,166 Reduced 4.8%	2,146,308 $142 Million
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $6.2 Million - $7.42 Million	-108,166 Reduced 4.8%	2,146,308 $142 Million
Q2 2024 May 14, 2025	SELL	$51.18 - $63.75 $29.8 Million - $37.1 Million	-582,613 Reduced 20.54%	2,254,474 $137 Million
Q2 2024 Oct 17, 2024	SELL	$51.18 - $63.75 $34.2 Million - $42.6 Million	-667,844 Reduced 22.85%	2,254,474 $137 Million
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $34.2 Million - $42.6 Million	-667,844 Reduced 22.85%	2,254,474 $137 Million
Q1 2024 Oct 17, 2024	BUY	$56.55 - $66.59 $37.8 Million - $44.5 Million	667,844 Added 29.62%	2,922,318 $166 Million
Q1 2024 Aug 16, 2024	SELL	$56.55 - $66.59 $24.5 Million - $28.9 Million	-433,380 Reduced 12.91%	2,922,318 $166 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $24.5 Million - $28.9 Million	-433,380 Reduced 12.91%	2,922,318 $166 Million
Q4 2023 Aug 16, 2024	BUY	$52.16 - $64.19 $57.4 Million - $70.7 Million	1,101,224 Added 48.85%	3,355,698 $211 Million
Q4 2023 Feb 13, 2024	BUY	$52.16 - $64.19 $64.5 Million - $79.3 Million	1,235,960 Added 58.31%	3,355,698 $211 Million
Q3 2023 Nov 15, 2023	BUY	$57.77 - $65.93 $10.8 Million - $12.4 Million	187,471 Added 9.7%	2,119,738 $122 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $2.04 Million - $2.52 Million	33,410 Added 1.76%	1,932,267 $120 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $838,616 - $1.03 Million	11,941 Added 0.63%	1,898,857 $137 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $28 Million - $35 Million	416,160 Added 28.3%	1,886,916 $152 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $22.9 Million - $28.7 Million	-345,866 Reduced 19.04%	1,470,756 $98 Million
Q2 2022 Oct 27, 2022	BUY	$66.18 - $83.18 $36.1 Million - $45.3 Million	544,741 Added 42.83%	1,816,622 $138 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $36.1 Million - $45.3 Million	544,741 Added 42.83%	1,816,622 $138 Million
Q1 2022 Oct 27, 2022	SELL	$66.02 - $79.71 $36 Million - $43.4 Million	-544,741 Reduced 29.99%	1,271,881 $101 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $32.2 Million - $38.8 Million	487,358 Added 62.12%	1,271,881 $101 Million
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $983,353 - $1.15 Million	-15,525 Reduced 1.94%	784,523 $57.6 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $54.9 Million - $67.2 Million	800,048 New	800,048 $55 Million

Others Institutions Holding INCY

# of Institutions

726

Shares Held

202M

Call Options Held

500K

Put Options Held

258K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $18.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account